In Rochester, New York, on March 07, 2025, Vaccinex, Inc. (OTC: VCNX) revealed its plan to delist its common stock from Nasdaq. The clinical-stage biotechnology company specializes in a unique approach to managing neurodegenerative diseases by targeting astrogliosis and neuroinflammation via SEMA4D inhibition. Following suspension from Nasdaq trading since December 18, 2024, the Company officially informed Nasdaq of its delisting decision. The common stock in question holds a par value of $0.0001 per share.
